Lite Strategy
LITS · NASDAQ
$1.19+$0.03 (+2.59%)TodayMarket closed ·
Prev close $1.16
EPS: actual vs estimate
Beat the estimate in 6 of the last 8 quarters, by 122.1% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q4 FY24 | -$1.46 | -$2.76 | −88.6% |
| Q3 FY24 | -$1.55 | -$1.37 | +11.6% |
| Q2 FY24 | -$1.35 | -$1.66 | −22.8% |
| Q1 FY24 | -$2.16 | $8.46 | +491.2% |
| Q4 FY23 | -$2.46 | -$1.51 | +38.7% |
| Q3 FY23 | -$2.92 | -$2.32 | +20.7% |
| Q2 FY23 | -$3.06 | $1.60 | +152.3% |
| Q1 FY23 | -$2.92 | -$2.40 | +17.9% |
Earnings calls
- MEIP - Earnings call 4 2023
- Infinity Pharmaceuticals, Inc., MEI Pharma, Inc. - Pre Recorded M&A Call
- Infinity Pharmaceuticals, Inc., MEI Pharma, Inc. - M&A Call
- Shareholder/Analyst Call - MEI Pharma, Inc.
- MEIP - Earnings call Q4 2022
- Special Call - MEI Pharma, Inc.
- Shareholder/Analyst Call - MEI Pharma, Inc.
- Special Call - MEI Pharma, Inc.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.